Theranica USA, Inc.

Theranica is a neuromodulation therapeutics company dedicated to creating effective, safe, affordable, and low-side-effect therapies for idiopathic pain conditions. Our initial focus is on migraine, one of the most common neurologic disorders affecting over 1 billion people, with a high prevalence and morbidity, especially among adolescents and females.

The company’s award-winning flagship Nerivio® REN wearable is changing the game for migraine sufferers, especially the 100 million adolescents facing this complex and non-curable disease. Nerivio is the first and only REN wearable that harnesses the natural power of the brain to shut off migraine symptoms without the use of drugs. With early intervention being key, Nerivio offers a safe and side-effect-free alternative, empowering adolescents to take control of their health and providing a foundation for complete migraine care as they transition into adulthood.

The Nerivio REN wearable is FDA-cleared and CE-marked for the acute and/or preventive treatment of migraine with or without aura in people 8 years of age or older. It has been used in more than 650,000 migraine treatments in the US, including by adolescents and veterans living with migraine. Learn more by visiting our websites, theranica.com, and nerivio.com. Indication & Safety Information: https://www.nerivio.com/isi